Stock BELL BELLUSCURA PLC
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Belluscura plc

Equities

BELL

GB00BD3B8Z11

Market Closed - London S.E.
Other stock markets
 11:35:23 2024-05-31 am EDT 		5-day change 1st Jan Change
13.25 GBX -.--% Intraday chart for Belluscura plc -15.87% -42.39%
May. 22 AIM WINNERS & LOSERS: Zenova scores NHS deal; Staffline "encouraged" AN
Apr. 02 Belluscura sees financial hit from delay to closing TMT acquisition AN

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • One of the major weak points of the company is its financial situation.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
BELLUSCURA PLC Stock Belluscura plc
-42.39% 27.82M -
ABBOTT LABORATORIES Stock Abbott Laboratories
-7.16% 178B
C+
MEDTRONIC PLC Stock Medtronic plc
-1.23% 107B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-4.86% 67.04B
A
DEXCOM, INC. Stock DexCom, Inc.
-4.28% 47.23B
B-
CENCORA, INC. Stock Cencora, Inc.
+10.32% 44.62B
B-
HOYA CORPORATION Stock Hoya Corporation
+8.14% 42.5B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+15.76% 29.99B
B
TERUMO CORPORATION Stock Terumo Corporation
+15.53% 25.22B
A-
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
-5.88% 24.14B
A-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. BELL Stock
  4. Ratings Belluscura plc